| [March 31, 2015] |
 |
STENTYS 2014 Annual Results
STENTYS (Paris:STNT) (FR0010949404 - STNT - PEA PME eligible), a
medical technology company commercializing the world's first and only
Self-Apposing® coronary stent, today reported
its financial results for the year to December 31, 2014, approved by the
Board of Directors on March 26, 2015. Audit procedures relative to the
consolidated accounts have been carried out and the auditor's report is
currently under finalization.
|
|
|
|
|
|
|
|
|
|
|
€ thousands - IFRS*
|
|
|
|
December 31, 2014
|
|
|
|
December 31, 2013
|
|
Revenues
|
|
|
|
3,851
|
|
|
|
3,394
|
|
Cost of goods sold
|
|
|
|
(2,314)
|
|
|
|
(2,038)
|
|
Research & Development
|
|
|
|
(6,762)
|
|
|
|
(4,697)
|
|
Sales & Marketing
|
|
|
|
(5,086)
|
|
|
|
(5,978)
|
|
General & Administrative
|
|
|
|
(2,808)
|
|
|
|
(2,467)
|
|
Other
|
|
|
|
8
|
|
|
|
|
|
Current operating loss (before share-based payment and
non-current expense)
|
|
|
|
(13,111)
|
|
|
|
(11,787)
|
|
Share-based payment
|
|
|
|
609
|
|
|
|
196
|
|
Non-current expense (APPOSITION V)
|
|
|
|
4,395
|
|
|
|
0
|
|
Operating loss
|
|
|
|
(18,116)
|
|
|
|
(11,983)
|
|
Net loss
|
|
|
|
(17,834)
|
|
|
|
(11,729)
|
|
APPOSITION V
|
|
|
|
(6,818)
|
|
|
|
(2,391)
|
|
Net loss excluding APPOSITION V
|
|
|
|
(11,016)
|
|
|
|
(9,338)
|
* Audited data
In 2015, STENTYS is beginning a new phase of its commercial development
via three successive product launches:
-
The self-apposing Sirolimus-eluting stent, STENTYS SES (News - Alert), which obtained
the CE mark at the end of October and whose deployment is continuing
in early 2015.
-
The MiStent SES®, the world's first drug-eluting stent with
a rapidly-bioabsorbable polymer coating and sustained drug release.
The controlled launch is scheduled in Europe during the first half of
the year.
-
The new delivery catheter, called Xposition, which allows
self-apposing stents to be implanted in the same manner as
conventional stents, is expected to be marketed during the second half
of the year.
Gonzague Issenmann, Chief Executive Officer and co-founder of
STENTYS, stated: "During 2014, we laid the groundwork for an
expansion and renewal of our cutting-edge product portfolio with the
goal of revitalizing STENTYS' development. The discontinuation of the
APPOSITION V clinical trial was one of the strategic choices that has
enabled us to focus our resources on the product launches that will
structure our activity in 2015."
To read the complete presse release, please click
here.
[ Back To TMCnet.com's Homepage ]
|
